In conscious rats, focal CO 2 stimulation of the medullary raphe increases ventilation, while interference with serotonergic function here decreases the ventilatory response to systemic hypercapnia. We sought to determine whether repeated administration of a selective serotonin reuptake inhibitor in this region would increase the ventilatory response to hypercapnia in unanaesthetized rats. In rats instrumented with EEG/EMG electrodes, 250 or 500 µM fluoxetine or artificial cerebrospinal fluid (aCSF) was microdialyzed into the medullary raphe for 30 minutes daily over 15 days. To compare focal and systemic treatment, two additional groups of rats received 10 mg*kg µM fluoxetine microdialysis showed a significant 13% increase in ventilation in wakefulness during hypercapnia on Day 7, due to an increase in tidal volume. In rats microdialyzed with 500 µM fluoxetine, there were 16% and 32% increases in minute ventilation during hypercapnia in wakefulness and sleep on Day 7, and 20% and 28% increases on Day 15; again due to increased tidal volume. There was no change in the ventilatory response to CO 2 in rats microdialyzed with aCSF, or in systemically treated rats. Chronic fluoxetine treatment in the medullary raphe increases the ventilatory response to hypercapnia in an unanaesthetized rat model, an effect that may be due to facilitation of chemosensitive serotonergic neurons.
INTRODUCTION
The medullary raphe nuclei of the mammalian brainstem, comprised of the raphe magnus, obscurus, and pallidus, are understood to modulate several homeostatic systems throughout the body. Serotonergic neurons that are located both within these nuclei and parapyramidally along the ventral surface of the medulla project to regions in the caudal brainstem and spinal cord involved in sensory, motor, and autonomic functions (12) .
These neurons have also been implicated in the ventilatory response to CO 2 (11, 33, 34, 41, 43, 54, 55) . Moreover, electrical and chemical stimulation of the medullary raphe nuclei affects phrenic nerve output (3, 27) , and antidromic stimulation of the phrenic motor nucleus at the C4 spinal level has been found to directly activate a population of medullary raphe neurons (21) .
With regard to respiration, the medullary raphe nuclei have been shown to be one of several brainstem regions of central chemoreception (4) , which can be defined as regions capable of specifically responding to changes in tissue pH and/or P CO2 by increasing ventilation in the whole animal (38) . In one study, microdialysis delivery of aCSF equilibrated with 25% CO 2 to the medullary raphe at the level of the facial nucleus increased frequency and ventilation by 15-20% in an unanaesthetized rat model, and the effect was only seen in non-REM (NREM) sleep (41) . A similar study performed in unanaesthetized goats found that microdialysis of aCSF equilibrated with 25% and 80% CO 2 increased ventilation by 8% and 12% respectively, however in this experiment the ventilatory effect was not observed in NREM or REM sleep (20) . These data suggest that medullary raphe chemosensitivity may vary across arousal states, as serotonergic medullary raphe neurons are most active during wakefulness, less active through the stages of NREM sleep, and fall nearly silent during REM (23) . Chemosensitivity of medullary raphe neurons has also been demonstrated specifically in primary tissue culture, revealing two morphologically distinct subsets of chemosensitive neurons; one which increases firing rate in response to acidosis/P CO2 increase and one that is inhibited by it (56) . Further in vitro studies exploring the neurochemical phenotypes of chemosensitive medullary raphe neurons revealed that acidosis/P CO2 -stimulated medullary raphe neurons are entirely serotonergic, whereas acidosis/P CO2 -inhibited neurons are not (57) . Taken together, these studies suggest that the chemoreceptive properties of the medullary raphe nuclei are functionally linked to serotonergic mechanisms.
There is additional evidence in whole-animal studies that suggest serotonergic function in the medullary raphe nuclei is important for the ventilatory response to hypercapnia. Inhibition of medullary raphe neurons by focal microdialysis of the GABA A receptor agonist muscimol (10 mM) significantly reduced ventilation by 17% in an unanaesthetized piglet model during a 5% CO 2 challenge but not in room air breathing (34) . Specific inhibition of serotonergic neurons in the medullary raphe via microdialysis of the 5HT 1A autoreceptor agonist 8-hydroxy-2-di-N-propylaminotertralin was also capable of decreasing the ventilatory response to 5% CO 2 during wakefulness in an unanaesthetized piglet model, as long as the piglets were over ten days old (33) . In a focal lesioning study performed recently, targeted killing of serotonergic neurons in the medullary raphe nuclei and parapyramidal regions of a rat model using microinjection of a serotonin transporter (SERT) antibody-saporin conjugate led to a 15% and 18% decrease in ventilation during 7% CO 2 during sleep and wakefulness respectfully.
Immunohistological analysis confirmed that only serotonergic neurons were effected by the treatment, and that 28% of these neurons were destroyed using the targeted cytotoxin (43) . Therefore, serotonergic neurons in the medullary raphe are capable of influencing ventilation during hypercapnia in fully conscious animal models during sleep and wakefulness.
Due to the fact that disruption of serotonergic neurons leads to a decrease in the ventilatory response to hypercapnia in conscious mammals, and serotonergic neurons in the medullary raphe exhibit chemosensitivity in both in vivo and in vitro studies, we hypothesize in this study that focal facilitation of serotonergic activity in the medullary raphe will lead to an increase in the ventilatory response to hypercapnic stress. In an attempt to increase serotonergic function in only medullary raphe neurons, we chose to microdialyze a solution containing the selective serotonin reuptake inhibitor (SSRI) fluoxetine directly into the medullary raphe nuclei at the level of the facial nucleus.
Fluoxetine, like other widely prescribed SSRI antidepressants, is capable of acutely increasing extracellular serotonin concentrations in the CNS. However, it does not show clinical efficacy until after several days of chronic treatment; suggesting long-term neurochemical changes are responsible for its therapeutic action (for review, see (53) ).
Taking this into consideration, we have developed our protocol to measure the ventilatory response to CO 2 in an unanaesthetized rat immediately, one week, and two weeks following daily fluoxetine microdialysis in the medullary raphe. We also considered the effect of sleep and wakefulness on ventilation, as the ability of medullary raphe neurons to influence the ventilatory CO 2 response may vary across different behavioral states.
Finally, we wanted to determine if systemic fluoxetine administration would change the ventilatory response to hypercapnia in a potentially similar manner as daily focal microdialysis using a similar ventilation protocol.
METHODS

Animals and Instrumentation.
Forty-two adult male Sprague-Dawley rats weighing 300-450 g were housed in a temperature-controlled environment on a 12:12 light-dark cycle, with the period of light taking place between midnight and noon to facilitate recording of ample sleep and wake data during the working day. Animals received rat chow and water ad libitum. All surgical and experimental protocols were approved by the Institutional Animal Care and Use Committee of Dartmouth College. Rats were allowed to recover for at least 4 days following surgical instrumentation before the start of experimentation.
Rats were anaesthetized with 100 mg/kg ketamine IM and 20 mg/kg xylazine IP and depth of anesthesia was evaluated throughout surgery by response to firm hind paw pinching. The abdominal surface, neck, and head were shaved and cleaned with betadine and 70% ethyl alcohol. A sterilized telemetric temperature probe (TA-F20, Data Sciences International, St. Paul, MN) was first inserted into the peritoneal cavity by an incision through the linea alba and the wound was closed.
The head of the animal was then secured and centered on a Kopf stereotaxic apparatus, and the surface of the skull was exposed. Three EEG electrodes were screwed into the right side of the skull; one placed 2 mm rostral to bregma and 2 mm lateral to the midline, one placed 2 mm rostral to lambda and 2 mm lateral to the midline, and a ground electrode was placed laterally between the two. Two wire EMG electrodes and a ground were then inserted into the neck skeletal muscles, and all electrode wires were put into a small 6-prong plastic pedestal. In animals receiving microdialysis, a microdialysis probe cannula with a dummy insert was placed 11.0-12.8 mm caudal to bregma and 0 mm from the midline, and 10.4-10.6 mm below the dorsal surface of the cerebellum into the of the medullary raphe nuclei at the level of the facial nucleus. Skull measurements were in accordance with the rat stereotaxic atlas of Paxinos and Wilson (46) . The EEG/EMG electrodes and probe cannula were secured onto the surface of the skull with cranioplastic cement, and the skull incision was sutured.
Microdialysis.
The microdialysis probe used in this study had an 11 mm stainless steel shaft Concentrations of fluoxetine in dialysate were chosen based upon a previous study using in vivo microdialysis of fluoxetine in rats (59) .
Systemic Administration of Fluoxetine.
In the rat groups receiving systemic drug administration, animals were reanaesthetized and an osmotic mini-pump (Alzet 2ML4, Durect Corp., Cupertino, CA) fluoxetine for the 15-day period. This dose was chosen based upon previous studies employing mini-pumps for fluoxetine delivery in models of anti-depressant activity in rats (18, 58) . A sham control group of animals were implanted with osmotic mini-pumps containing vehicle only (75% polyethylene glycol and saline). Ventilation recording in the two systemic groups to determine acute fluoxetine effects on breathing took place 3 days following osmotic mini-pump implantation, so that animals had time to recover after this second surgery. After the 15-day period, animals were euthanized and the osmotic mini-pumps were removed. We checked each pump reservoir for any remaining solution, and assured that each animal included in data analysis had received the correct volume of drug or vehicle over the course of the experiment.
Ventilation, O 2 consumption, temperature, and EEG/EMG measurement.
Ventilation was recorded inside a whole-body plethysmograph as previously described (41, 42) based upon the setup of Jacky (22) and Pappenheimer (45) . Briefly, the analog signal from the pressure transducer was digitally converted and sampled at 150 Hz at a computer interface using the Datapac 2000 system (RUN Technologies, Laguna Hills, CA). The plethysmograph was at atmospheric pressure, with inflow and outflow rates balanced to one another. Inflow rates to the plethysmograph were kept ≥ . Inflow content of O 2 was measured at the beginning of the experiment before the rat was placed into the box. A thermometer inside the chamber provided chamber temperature (T c ), and rat body temperature (T b ) was measured using the analog signal generated by the telemetric temperature probe in the abdomen. EEG and EMG signals were sampled at 150 Hz and filtered at 0.3-50 and 0.1-100 Hz, respectively, and recorded on the computer interface system directly using the Datapac 2000 system.
Microdialysis Experimental Protocol.
There were three groups of animals in our experimental design: rats receiving microdialysis of aCSF (n = 8), 250 (n = 8), and 500 µM fluoxetine HCl (n = 10) in aCSF.
On Day 0 of the experiment (pretreatment), the rats were placed into the plethysmograph chamber and EEG/EMG were connected. Rats were allowed to acclimatize for at least thirty minutes and recording of ventilation did not commence until it was clear that the rat was relaxed and no longer exploring. Thirty minutes of ventilation data during room air were then recorded containing noticeable periods of sleep and wakefulness. Then the inflow of the plethysmograph was changed to a mixture of 7% CO 2 and room air (a moderate hypercapnic stress which produces marked increases in f and V T ) and thirty minutes of hypercapnic ventilation commenced when the plethysmograph reached 7% CO 2 according to the gas analyzer. On the second day of the experiment (Day 1), the microdialysis probe was primed with aCSF or fluoxetine solution and placed into the medulla. The animal was again placed into the plethysmograph chamber, and received 30 minutes of microdialysis treatment before beginning the ventilation experiment 
Systemic Administration Experimental Protocol.
The experimental protocol for rats receiving systemic fluoxetine (n = 8) or vehicle (n = 8) administration was identical to our microdialysis experiments with two exceptions: 1) the acute ventilation experiments were performed on Day 3 following osmotic mini-pump implantation so that rats were recovered from the second surgery; and 2) obviously, these rats did not receive microdialysis.
Data Analysis.
Sleep analysis was completed using both the raw EEG/EMG record and the fast Fourier transform of the EEG at 3.6 s-long epochs. Delta, theta, and sigma frequency bands were characterized as 0.3-5, 6-9, and 10-17 Hz, respectively. The ventilation experiments occurred at random times both before the dark period began in the housing environment (9 AM-noon) or after the dark period had began (noon-5 PM). States of arousal were defined as previously described (40, 41) . Wakefulness was characterized when the raw EEG signal was low, EMG activity was present, and delta power was low.
NREM sleep was characterized when the raw EEG signal was high, EMG activity was low, delta power was high, and the product of sigma and theta was high. REM periods were brief but characterized by low raw EEG signal, absent EMG activity, low delta power, and high theta to delta ratio. Respiration events that occurred during REM sleep were excluded, as the recording period in this study was not long enough to achieve ample REM in all experiments. There were also instances when it was difficult to determine sleep state, so respiration events from those periods were also excluded. When the amount of time spent in each sleep state was analyzed, REM periods were grouped together with the periods when the arousal state was indeterminate.
Ventilation was analyzed by examining individual breath events with the Datapac 2000 software. Sighs, sniffing, and periods of high rat activity (moving, grooming) were eliminated from the analysis, and post-sigh apneas were not included in the analysis. The frequency and raw pressure data were grouped into bins of ≥ 50 to 400 breath events, and differentiated by quiet wakefulness and NREM states. Data were exported to a spreadsheet, and tidal volume (V T ), breathing frequency (f), and minute ventilation (V E ) were calculated for each respiratory event using T C , T b , and the barometric pressure. V T and V E were normalized per 100 g rat body weight. V E , V T , and f are reported as mean values for quiet wakefulness and NREM sleep during room air breathing and hypercapnia over the course of each experimental day. All data were analyzed using one-way repeated measures (RM) and two-way ANOVAs, or t-tests as appropriate (Sigma-stat, Jandel Scientific). In certain cases, Friedman repeated measures ANOVA on ranks had to be performed. Post-hoc tests were performed when significant differences between treatments and/or experimental day were found.
RESULTS
Body Weight, Body Temperature, and Oxygen Consumption.
Mean body weights for each treatment group at the start (Day 0) and conclusion (Day 15) of the experimental period were as follows (± SEM): aCSF microdialysis group 328.4 ± 17.9 and 338.9 ± 17.7 g; 250 µM fluoxetine microdialysis group 307.2 ± 22.2 and 325.4 ± 19.3 g; 500 µM fluoxetine microdialysis group 331.2 ± 17.6 and 347.1 ± 14.6; systemic vehicle group 343.6 ± 18.3 and 381.5 ± 16.1 g; and the systemic fluoxetine group 310.4 ± 9.2 g and 345.2 ± 6.6 g. The Day 0-15 increases seen in body weight within the three rat groups receiving microdialysis did not differ significantly from each other, nor did the increases seen in the two systemically treated groups (oneway ANOVA with treatment as the factor). Repeated fluoxetine (250 and 500 µM) or aCSF microdialysis into the medullary raphe did not significantly alter core body temperatures in room air or in 7% CO 2 . Similarly, chronic systemic infusion of vehicle or 10 mg*kg
fluoxetine did not change core body temperatures seen during our ventilation experiments. Oxygen consumption during normocapnic breathing, calculated by application of the Fick principle, also did not change significantly within any of our treatment groups during the 15-day experimental period. Statistical analyses of oxygen consumption and core body temperature data were done using one-way RM ANOVA using experiment day as the factor, with each animal serving as its own pre-treatment (Day 0) control.
Sleep States.
We categorized vigilance states into periods of quiet wakefulness (QW), non-REM (NREM), and indeterminate (I, which included any periods of REM) during our ventilation experiments based on EEG/EMG activity as described. It is important to reiterate that these experiments were designed to measure ventilation with regards to sleep state, and to be able to detect any potentially large changes in ventilation during QW or NREM states due to drug administration; however, our 30-minute recording period during room air (and 7% CO 2 ) is not long enough to adequately describe changes in sleep cycling due to fluoxetine. Percent experimental time spent in QW and NREM states during the 30-minute room air and 7% CO 2 recording periods on the four experimental days are shown in Table 1 . Percent time in I state never amounted to more than 3% of the experimental time in any rat group. There were no significant changes in percent time in QW, NREM or I states over the 15-day experiment in any of the five treatment groups when each animal served as its own control (one-way RM ANOVA with experiment day as the factor). We also found no change in the percent time in QW, NREM, or I states over the 15 days when aCSF, 250, and 500 µM fluoxetine microdialysis groups or when the systemic vehicle and 10 mg*kg 
Ventilation and Fluoxetine Microdialysis into the Medullary Raphe.
Ventilation data from the rat group that received daily 30-minute microdialysis treatments of aCSF alone are shown in Figure 1 . Chronic aCSF microdialysis did not effect V E , V T , or f during normocapnia or during 7% CO 2 breathing (one-way RM ANOVA with experiment day as the factor). Ventilation parameters during QW were similar to those seen in NREM.
In rats that received microdialysis treatments of aCSF containing 250 µM fluoxetine, V E , V T , and f during room air recording did not change significantly over the experimental period in QW (Figure 2 ). Due to technical problems, we were not able to obtain sleep data for four of the rats in this group, preventing statistical analysis of NREM ventilation parameters. During 7% CO 2 On Day 15, V T during 7% CO 2 breathing appeared to remain elevated, however this was not significant in post-hoc analysis. NREM ventilation data during hypercapnia mirrored that of QW, but it could not be analyzed due to the small subject size.
When the concentration of fluoxetine in the dialysate was increased to 500 µM, V E , V T , and f during room air breathing did not change over the experimental period in either QW or NREM (Figure 3 Upon measurement of osmotic mini-pump reservoir volume at the conclusion of all systemic experiments, it was found that every rat had received the appropriate volume of either vehicle or fluoxetine solution.
Comparison among Microdialysis and Systemically Treated Groups.
The design of this experiment was such that each animal would serve as its own pre-treatment (Day 0) control on subsequent experimental days over a two-week period.
We also had in place an aCSF microdialysis group and a systemic vehicle group to serve as sham controls for multi-group comparisons in our focal and systemic experiments, and to evaluate any non-specific effects of microdialysis probe or osmotic mini-pump placement. The primary ventilation effect that we saw during fluoxetine microdialysis into the medullary raphe was a significant increase in V E during hypercapnia on Days 7
and 15 due to an increase in V T . Therefore, we compared the percent change in absolute ventilation during 7% CO 2 in aCSF, 250, and 500 µM fluoxetine groups to determine if the groups differed from one another (Figure 8 ). We found that the percent change in V E on Days 1, 7, and 15 during hypercapnic breathing was significantly higher in the 500 µM fluoxetine microdialysis group compared to the aCSF microdialysis group in both QW and NREM (p ≤ 0.05, two-way ANOVA with treatment and experiment day as factors, Dunnett post-hoc comparison to aCSF), although there was no significant interaction between treatment and experiment day. The 250 µM fluoxetine microdialysis group showed an increased percent change in hypercapnic V E in QW and NREM, but this was not significant. We also compared percent change in hypercapnic V E during QW and NREM between our systemic vehicle and 10 mg*kg
fluoxetine groups, but there was no difference found in either treatment or experiment day nor was there an interaction (two-way ANOVA, data not shown).
DISCUSSION
The data in this study show that daily focal fluoxetine microdialysis into the medullary raphe nuclei of the rat over a 15-day period can enhance the ventilatory response to moderate hypercapnia during both quiet wakefulness and NREM sleep in an unanaesthetized rat model. The increase in hypercapnic ventilation was due to an increase in tidal volume and not in breathing frequency, and the response did not become clear until after several days of microdialysis treatments had taken place. Microdialysis of the larger 500 µM concentration led to the larger increase in the hypercapnic response, a 16% and 32% increase in V E in 7% CO 2 conditions during wakefulness and sleep on To our knowledge, this is the first study that has used repeated daily reverse microdialysis of an SSRI in a region of serotonergic neurons over the course of two weeks. There have been other studies in which microdialysis was used to deliver fluoxetine to different rat brain regions; for example, the arcuate nucleus and nucleus accumbens (59), the mediobasal hypothalamus (32), the striatum (30), and the frontal cortex (14) . However, these studies only considered the acute effects of fluoxetine microdialysis on neurotransmitter concentrations. In this study we used chronic fluoxetine microdialysis in an attempt to enhance the function of serotonergic neurons located in the medullary raphe, and perhaps potentiate their chemoreceptive properties.
Due to the fact that SSRIs have a delayed onset of therapeutic action of two to four weeks, we hypothesized that changes in the ventilatory response to CO 2 might also be delayed. Indeed, significant increases in hypercapnic ventilation as a result of fluoxetine microdialysis were not present on experimental Day 1, but did become evident on Days 7 and 15; suggesting that longer-term neurochemical changes in serotonergic neurons brought about by chronic fluoxetine may be involved.
Repeated Fluoxetine Microdialysis Effects on Medullary Raphe Serotonergic Neurons.
It is still unclear as to how SSRI compounds lead to clinical benefit, and why this takes days to weeks to occur. In our present experiments, there are several mechanistic possibilities to explain how repeated focal fluoxetine microdialysis might affect the way medullary raphe neurons modulate the ventilatory response to CO 2 . When administered acutely, SSRIs increase extracellular serotonin due to SERT blockade at serotonergic cell bodies, which initially decreases serotonergic neuron firing activity due to 5HT 1A autoreceptor activation (8, 15) . With continued SSRI treatment, the 5HT 1A autoreceptor can be desensitized to heightened extracellular 5HT, allowing serotonergic activity to resume (5) . Functional desensitization of somatodendritic 5HT 1A receptors in serotonergic neurons after chronic SSRI treatment has been described in the dorsal raphe (26, 28, 35, 47) , so it is feasible that somatodendritic 5HT 1A receptors located on chemosensitive medullary serotonergic cell groups may also become desensitized and enhance serotonergic tone post-synaptically after chronic fluoxetine microdialysis.
Desensitization of the 5HT 1A is not the only mechanism that explains the delayed 
Focal Fluoxetine Microdialysis into the Medullary Raphe vs. Systemic Administration.
Understanding why focal fluoxetine treatment of serotonergic neurons in the medullary raphe increased the ventilatory response to hypercapnia, while systemic fluoxetine treatment did not might prove to be complex. We suggest two possible explanations for this: 1) different concentrations of fluoxetine reaching SERT located within serotonergic cell groups in the rat brain during focal or systemic administration and 2) the functional consequences of chronic blockade of serotonin re-uptake only in the medullary raphe as opposed to throughout the entire brain.
For the microdialysis studies, we chose the initial concentration of 250 µM fluoxetine as a reasonable starting point based upon a study that used reverse microdialysis delivery (59) , and also a second larger concentration of 500 µM. The higher concentration of fluoxetine microdialyzed did result in a clearer increase in hypercapnic ventilation. In one study that measured concentrations of glutamate in brain tissue 1.5 mm away from the point of microdialysis probe delivery, there was a 10-100 fold drop in drug concentration from the probe tip (10) . Thus, we could expect the concentration of fluoxetine in a 1.5 mm radius to fall from 250 and 500 µM at the probe tip to 2.5-25 and 5.0-50 µM. This would also largely depend upon the diffusion properties of fluoxetine through brain tissue. Diffusion of a cationic molecule through the extracellular space within brain tissue from a point source, such as a microdialysis probe, depends upon tortuosity (the path length a particle must navigate in a complex medium) and volume fraction (the amount of fluid found in the extracellular space) (44).
However, the diffusion of fluoxetine through brain tissue may be even more complex because it is highly lipophilic, it is taken up by glia and neurons, and it can nonspecifically bind to different subcellular compartments (37) . The ability of fluoxetine to bind to non-specific proteins and lipids within neuronal cells may suggest in our microdialysis experiments that it could be present at bioactive concentrations for a period of time after microdialysis is stopped; as fluoxetine has a relatively low IC 50 of 6.8 nM (51) . Acute microdialysis of 100 µM fluoxetine into the frontal parietal cortex of rats (an area that has less SERT density than serotonergic raphe nuclei) can lead to a 6-10 fold increase in basal 5HT concentration after 140 minutes of dialysis (16) . It is logical to suppose that in our protocol, which used shorter daily 30-minute microdialysis treatments, a higher concentration of fluoxetine was required to increase extracellular 5HT to a point where long-term changes in serotonergic transmission and could take place and alter the ventilatory response to hypercapnia.
In contrast to local brain tissue fluoxetine concentrations that may approach 25-50 µM during reverse microdialysis, systemic 10 mg*kg . While these concentrations are smaller than those we approximated during focal microdialysis, they remain constant so long as the mini-pump functions. This dose given systemically is able to alter rat performance in behavioral paradigms suggestive of anxiolytic effects (18, 58) , and also results in a significant decrease in dorsal raphe serotonergic neuron firing rates after 3 days (due to 5HT 1A autoreceptor activity), followed by a recovery to baseline firing rates at 14 days (9). The magnitude and temporal aspects of the effect on serotonergic neuron activity are not different when the fluoxetine doses are decreased to 5 or increased to 20 mg*kg
Therefore, the 10 mg*kg
dose we chose for our study can be considered physiologically appropriate from a behavioral perspective. Taking into account that the systemic dose used in our study leads to documented functional changes in firing rates of rat serotonergic neurons, we believe the lack of ventilation effect in systemically treated rats is probably not due to dose or route of administration, but is due to differences in effecting serotonin reuptake in one subset of serotonergic neurons versus SERT throughout the entire brain.
If the effects of fluoxetine on serotonergic neurotransmission differ depending on whether it is applied locally or systemically, it is not easy to speculate what these differences may be, especially because it is not completely understood how SSRIs affect serotonergic neurons. Desensitization of somatodendritic 5HT 1A receptors located on chemosensitive neurons in the medullary raphe could result in increased serotonergic tone at post-synaptic pre-motor sites involved in increasing the ventilatory response, although our studies have not addressed this at the present time. In comparison, chronic systemic fluoxetine administration might potentially lead to desensitization of 5HT 1A
receptors located both pre-and post-synaptically on serotonergic and on non-serotonergic neurons; effecting other brain regions and neuronal circuits which can modulate ventilation, perhaps counteractively. The nucleus tractus solitarius is one such region involved in ventilatory control where input from the rostral nucleus raphe magnus (which primarily contains serotonergic neurons) has an inhibitory, not excitatory, effect on ventilation in rats during hypoxia (13, 48) . Thus, the results observed in the present study in rats treated with fluoxetine locally opposed to systemically might indicate that serotonergic influence on ventilation might serve different functional roles, depending upon the neuronal circuits exposed to chronic SSRI treatment.
Fluoxetine, Arousal State, and the Ventilatory Response to CO 2 .
In the present study, we found that fluoxetine microdialysis into the medullary raphe over a period of 15 days led to similar increases in the response to 7% CO 2 during NREM sleep and wakefulness (Figures 2 and 3) . However, not all studies involving brainstem chemosensitive regions show similar ventilatory effects across arousal states.
In the retrotrapezoid nucleus, 25% CO 2 microdialysis increased ventilation in wakefulness only, due entirely to an increase in tidal volume (29) . In the nucleus tractus solitarius, 25% CO 2 microdialysis increased ventilation in wakefulness and in NREM and REM sleep due to an increase in both frequency and in tidal volume (40) . Within the medullary raphe region, 25% CO 2 microdialysis increased ventilation only in NREM and REM sleep as a result of increased frequency, whereas in an unanaesthetized goat model 25% or 80% CO 2 microdialysis increased ventilation only during quiet wakefulness (20, 41) . These results suggest that each brainstem region that acts as a central chemoreceptor site has a particular function which is also dependant upon the arousal/behavioral state of the animal, or the animal model used (for reviews, see (19, 39) ).
Our results after focal or systemic chronic fluoxetine administration did not suggest that any drastic changes in sleep cycling occurred as a result of treatment, as there were no differences found in the percent time spent in wakefulness or in NREM sleep over the course of the experiments (Table 1a and 1b). However, the fact that we did not see any significant differences in percent time spent in any arousal state with either focal fluoxetine microdialysis or systemic administration can most likely be attributed to the short duration of our ventilation experiments. This study was not designed to accurately study sleep cycling, as much longer recordings over the course of the photoperiod are required to do so; especially to observe periods of REM sleep in the rat. Therefore we realize it is possible that either focal microdialysis into the medullary raphe or systemic administration of fluoxetine might have altered sleep cycling during the 15-day experiments.
Conclusions.
Serotonergic neurons located within the medullary raphe (and those located parapyramidally along the ventral surface of the brainstem) modulate a variety of functions such as repeated motor activity (23), pain processing and arousal (31), cardiovascular control (7), thermoregulation (36), ventilatory control (27) and chemosensitivity (56) . These neurons have the ability to specifically respond to CO 2 in vivo (4, 20, 41) and in vitro (57) , are located adjunct to large medullary arteries (6), project to brainstem respiratory groups (52) , and project to spinal motor neurons effecting phrenic nerve output (50) . Of clinical relevance, anatomical abnormalities in serotonergic medullary raphe neurons have been found in victims of the sudden infant death syndrome (SIDS) (25) .
A central hypothesis of our laboratory and of others has been that disrupting serotonergic activity within the medullary raphe and extra-raphe cell groups results in a decreased ventilatory response to hypercapnia. The data in the present study, that shows an increased ventilatory response to hypercapnia after chronic microdialysis treatments with the SSRI fluoxetine, is the first to suggest that the opposite might occur. The . * *
